Comparative Pharmacology
Head-to-head clinical analysis: JAIMIESS versus NORTREL 1 35 21.
Peer-Reviewed Evidence
Head-to-head clinical analysis: JAIMIESS versus NORTREL 1 35 21.
JAIMIESS vs NORTREL 1/35-21
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Norepinephrine and dopamine reuptake inhibitor; also weakly inhibits serotonin reuptake. Enhances synaptic concentrations of norepinephrine and dopamine, particularly in prefrontal cortex.
Combination of ethinyl estradiol (estrogen) and norethindrone (progestin) suppresses gonadotropin (FSH and LH) release from the pituitary, inhibiting ovulation, altering cervical mucus to impede sperm penetration, and inducing endometrial changes that reduce implantation likelihood.
100 mg orally once daily with food.
One tablet orally once daily for 21 days, followed by 7 days off, then repeat.
None Documented
None Documented
Terminal elimination half-life is approximately 12-15 hours in healthy adults; prolonged in renal impairment (up to 30 hours in severe impairment).
Norethindrone: 5-14 hours; Ethinyl estradiol: 17-24 hours. Steady-state achieved after 10 days.
Primarily renal excretion as unchanged drug (approximately 70%) with the remainder as inactive metabolites; less than 10% excreted in feces.
Renal 50-60% as metabolites, fecal 40-50% as conjugates, <1% unchanged
Category C
Category C
Oral Contraceptive, Combined
Oral Contraceptive